SteelPeak Wealth’s BioMarin Pharmaceuticals BMRN Stock Holding History

SteelPeak Wealth’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-2,498	Closed	-$218K	–	545
2024 Q1	$218K	Buy	2,498 +246	+11%	+$22K	0.01%	417
2023 Q4	$217K	Buy	+2,252	New	+$199K	0.01%	381
2023 Q3	–	Sell	-5,106	Closed	-$443K	–	453
2023 Q2	$443K	Sell	5,106 -2,726	-35%	-$257K	0.03%	260
2023 Q1	$762K	Buy	7,832 +3,531	+82%	+$366K	0.05%	184
2022 Q4	$445K	Buy	+4,301	New	+$404K	0.03%	263

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

SteelPeak Wealth's BMRN Position: Q2 2024 in Review

SteelPeak Wealth sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2024, closing a stake of 2,498 shares — an estimated $218K sold.

SteelPeak Wealth first reported a position in BMRN in Q4 2022 and held it in 5 quarters. The position peaked at $762K in Q1 2023. 558 funds tracked by Wall St. Rank hold BMRN as of Q2 2024.

SteelPeak Wealth reported no remaining BioMarin Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
SteelPeak Wealth sold 2,498 BioMarin Pharmaceuticals shares in Q2 2024, an estimated $218K.
SteelPeak Wealth first reported a position in BioMarin Pharmaceuticals in Q4 2022 and held it in 5 quarters.
SteelPeak Wealth's BioMarin Pharmaceuticals position peaked at $762K in Q1 2023.
558 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2024.

Based on SteelPeak Wealth's 13F filing for Q2 2024, filed 17 Jul 2024.